FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Expression Vector topics
Expression Vector
Recombinant
Nucleic Acid
Antibodies
Polypeptide
Amino Acid
Amino Acid Sequence
Nucleic Acids
Polynucleotide
Nucleotide
Cytomegalovirus
Endothelial
Extracellular
Endothelial Cell
Epithelial

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Expression Vector patents



      
           
This page is updated frequently with new Expression Vector-related patent applications. Subscribe to the Expression Vector RSS feed to automatically get the update: related Expression RSS feeds. RSS updates for this page: Expression Vector RSS RSS


Date/App# patent app List of recent Expression Vector-related patents
11/20/14
20140342407
 Neutralizing gp41 antibodies and their use patent thumbnailnew patent Neutralizing gp41 antibodies and their use
Monoclonal neutralizing antibodies are disclosed that specifically bind to the hiv-1 gp41 membrane-proximal external region (mper). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids.
11/20/14
20140342401
 Promoter derived from human gene patent thumbnailnew patent Promoter derived from human gene
The present invention relates to a transfected mammalian host cell whose ability to secrete a foreign protein has been enhanced by using a foreign gene expression vector having a promoter derived from a human gene, and a method for producing the foreign protein using the host cell. A method for enhancing the production of a foreign protein to be used in a pharmaceutical protein product in a host cell such as a cultured mammalian cell is provided.
11/20/14
20140341897
 Anti-folate receptor alpha antibodies and uses thereof patent thumbnailnew patent Anti-folate receptor alpha antibodies and uses thereof
Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits.
11/20/14
20140341852
 Capsid-modified raav vector compositions and methods therefor patent thumbnailnew patent Capsid-modified raav vector compositions and methods therefor
Disclosed are capsid-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated raav constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors.
11/13/14
20140335622
 Expression vector and method for producing protein patent thumbnailExpression vector and method for producing protein
Provided are: an expression vector for secreting a protein (z) to be recovered or a fusion protein having the protein (z) moiety therein; a method for producing a transformant using the expression vector; the transformant; and a method for producing a protein using the transformant. An expression vector comprising an expression cassette containing a structural gene sequence (y) encoding a protein (y), a structural gene sequence (z) located downstream from the structural gene sequence (y) and encoding a protein (z) that is a protein to be recovered, and a promoter sequence and a terminator sequence for expressing a fusion protein containing the protein (y) moiety and the protein (z) moiety, characterized in that the protein (y) is a full-length protein of protein disulfide isomerase 1 (pdi1), a partial protein of pdi1, or a mutant protein of the full-length protein or the partial protein..
11/13/14
20140335516
 Inducible cell-based model for the study of friedreich's ataxia patent thumbnailInducible cell-based model for the study of friedreich's ataxia
Isolated transduced cells exhibiting frda characteristics in an inducible fashion are disclosed. Isolated transduced cells comprise an expression vector having a nucleic acid sequence encoding an shrna for frataxin protein knockdown and a heterologous expression control sequence.
11/13/14
20140335097
 Expression vector patent thumbnailExpression vector
The present invention provides an expression vector for cell-surface expression of proteins.. .
11/06/14
20140331360
 Plant viral expression vectors and use of same for generating genotypic variations in plant genomes patent thumbnailPlant viral expression vectors and use of same for generating genotypic variations in plant genomes
A method of generating genotypic variation in a genome of a plant is disclosed. The method comprising introducing into the plant at least one viral expression vector encoding at least one chimeric nuclease which comprises a dna binding domain, a nuclease and a localization signal to a dna-containing organelle, wherein the dna binding domain mediates specific targeting of the nuclease to the genome of the plant, thereby generating genotypic variation in the genome of the plant..
11/06/14
20140328833
 Methods for treating cancer using anti-pd-1 antibodies patent thumbnailMethods for treating cancer using anti-pd-1 antibodies
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/30/14
20140322778
 Production of isopropanol by improved recombinant strains patent thumbnailProduction of isopropanol by improved recombinant strains
The expression vector includes: the nucleic acids coding for the polypeptides forming a polypeptide complex having an enzyme activity allowing acetoacetyl-coa to be converted to acetoacetate; optionally, at least one nucleic acid coding for a polypeptide having an enzyme activity allowing acetoacetate to be converted to acetone; and at least one nucleic acid coding for a polypeptide having an enzyme activity allowing acetone to be converted to isopropanol; the expression of the nucleic acids being controlled by a single constitutive promoter located upstream of the abovementioned nucleic acids.. .
10/30/14
20140322301
Mucin antigen vaccine
Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.
10/30/14
20140322205
Rtef-1 variants and the use thereof for inhibition of angiogenesis
Dominant negative (dn) variants of transcriptional enhancer factor 1-related (rtef-1) are described. Dn rtef-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription.
10/30/14
20140322160
Method and composition for altering a b cell mediated pathology
The present invention provides compositions for altering a b cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins.
10/23/14
20140317785
Specific genetic modification of the activity of trehalose-6-phosphate synthase and expression in a homologous or heterologous environment
A method for the preparation of a eukaryotic organism, for example selected from plants, animals and fungi, showing constitutive, inducible and/or organ specific expression of a specifically modified tps gene, which comprises the steps of providing a tps gene; designing a suitable modification to the tps gene by aligning the gene with the corresponding gene of yeast and establishing which part of the gene extends beyond the 5′ terminus of the yeast gene; deleting or inactivating a part of the n-terminal region of the tps gene extending beyond the 5′ terminus of the yeast gene, in order to achieve an increased trehalose-6-phosphate synthase activity; cloning the thus modified gene into an expression vector under the control of a constitutive, inducible and/or organ-specific promoter; transforming a plant cell or tissue with the thus obtained expression vector; and regenerating a complete plant from the transformed plant cell or tissue.. .
10/23/14
20140315987
Cholecystokinin b receptor (cckbr) mini-promoters
Isolated polynucleotides comprising a cckbr mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
10/23/14
20140315272
Novel lipolytic enzyme lip2
The present invention provides a novel nucleic acid sequence, designated lip2, encoding a lipolytic enzyme and the corresponding encoded amino acid sequences. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding at least one novel lipolytic enzyme, recombinant lipolytic enzyme proteins and methods for producing the same..
10/23/14
20140315247
Expression cassette, use of the expression cassette, expression vector, prokaryotic host cell comprising expression vector, bacterial strain and a method for producing a polypeptide
The subject matters of invention relate to expression cassette, use of the expression cassette, expression vector, prokaryotic host cell harbouring expression vector, bacterial strain, and method for producing a polypeptide. In more detail, the invention relate to stable expression of recombinant polypeptides, in systems with no need of using antibiotics.
10/23/14
20140315234
Method to generate dopaminergic neurons from mouse and human cells
The present invention relates to a method for reprogramming a differentiated non neuronal cell into a dopaminergic neuron comprising the step of inducing the expression in the differentiated non neuronal cell of at least the protein encoded by the mash1 human gene or orthologues thereof and the protein encoded by the nurr1 human gene or orthologues thereof, expression vectors, reprogrammed dopaminergic neuron and uses thereof.. .
10/23/14
20140314858
Ipnv-isav bivalent vaccine using a virus-like particle-based platform and methods of using the same
The present invention provides bivalent oral vaccines against infectious pancreatic necrosis virus (ipnv) and infectious salmon anemia virus (isav). Yeast cells comprise an expression vector comprising (i) a polynucleotide sequence encoding a vp2 capsid protein of ipnv and (ii) a polynucleotide sequence encoding one or more antigenic epitopes of hemaglutinin of isav.
10/16/14
20140308731
Novel cytochrome p450 enzymes from sorghum bicolor
Two novel cytochrome p450 genes are isolated from sorghum, each gene encoding a protein having pentadecatrienyl resorcinol hydroxylase activity. Expression vectors containing these sequences are made and used to elevate levels of pentadecatrienyl resorcinol hydroxylase in transgenic cells and organisms..
10/16/14
20140308240
Therapeutic agent for infections, and treatment method using same
(means for solving problems) the present invention provides a therapeutic agent for infections comprising as active ingredient: 15k granulysin, a combination of 15k granulysin and 15k granulysin in vivo expression vector, a combination of 15k granulysin and at least one interleukin selected from il-6, il-23 or il-27, a combination of 15k granulysin in vivo expression vector and at least one interleukin selected from il-6, il-23 or il-27, or a combination of 15k granulysin in vivo expression vector and hsp65dna and il-12dna in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.. .
10/02/14
20140296320
Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide
The present invention relates to the combinatorial use of an sirna targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression in the host of the protein encoded by the polynucleotide.. .
10/02/14
20140296137
Methods and compositions for controlling rotifers
Described herein are compositions and methods for controlling, inhibiting, reducing and/or preventing rotifer growth with antimicrobial peptides. Methods for removing and/or preventing rotifer infestations in algae cultivations by controlling, inhibiting, reducing and/or preventing rotifer growth with an antimicrobial peptide (amp) are further provided.
10/02/14
20140296101
Secreted proteins and uses thereof
The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies.
10/02/14
20140295497
Vectors and host cells comprising a modified sv40 promoter for protein expression
The present disclosure is directed to expression vectors, comprising a weakened sv40 promoter, and recombinant mammalian cells capable of producing high levels of a polypeptide of interest, methods of generating and using such recombinant mammalian cells.. .
10/02/14
20140294941
Anti-angiogenic compositions and therapeutic applications thereof
There is described the use of the human herpesvirus type 6 (hhv-6) u94 gene and its product, the protein rep, expression vectors and pharmaceutical compositions suitable for the delivery of the u94 gene or the protein encoded therefrom to the therapeutic sites, to inhibit angiogenic and lymphangiogenic processes in a subject in need thereof.. .
10/02/14
20140294867
Site-specific antibody-drug conjugation through glycoengineering
The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or adcs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
10/02/14
20140294852
Monoclonal antibodies to programmed death 1 (pd-1)
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/02/14
20140294813
Tnf binding proteins
Provided are tnf binding proteins and methods of treatment using the same. Also provided are nucleic acids encoding the binding proteins and recombinant expression vectors and host cells for making such binding proteins..
09/25/14
20140289901
Modulating beta-damascenone in plants
A mutant, non-naturally occurring or transgenic plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a neoxanthin synthase and having at least 60% sequence identity to seq id no:1 or seq id no. 6; (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide having at least 66% sequence identity to seq id no:2 or at least 60% sequence identity to seq id no.
09/25/14
20140287480
Hbv polymerase mutants
The present invention relates to polymerase hbv mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to hbv with the goal of providing a protective or therapeutic effect against hbv infection..
09/25/14
20140286954
Tau protease compositions and methods of use
Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and analytical assays..
09/25/14
20140286907
Transient expression vectors, preparation and uses thereof
The present invention describes a recombinant retroviral vector which cannot by itself achieve complete reverse transcription as well as its uses, in particular for transiently transferring in vitro, ex vivo or in vivo at least one ribonucleic acid sequence of interest in a cell. Such a transient transgene expression is of interest in the context of research, therapy and more generally in the field of biotechnology..
09/18/14
20140283208
Novel insecticidal proteins and methods of use
Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
09/18/14
20140283157
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
The invention provides isolated anti-lp-pla2 antibodies that bind to lp-pla2. The invention also encompasses compositions comprising an anti-lp-pla2 antibody.
09/18/14
20140283154
Transgenic insect cells comprising a bacterial glcnac-6-p 2prime-epimerase
The present invention relates to methods of facilitating the expression of recombinant polypeptides from cells, extracellular fluids, extracellular fibers, or any combination thereof, obtained from transgenic insect cells and larvae comprising a bacterial glcnac-6-p 2′-epimerase (gnpe), which is capable of converting n-acetyl-d-glucosamine-6-phosphate (glcnac-6-p) to n-acetyl-d-mannosamine-6-phosphate (mannac-6-p). The invention relates to methods to promote efficient glycoconjugate sialylation, by providing simpler ways to produce large intracellular pools of sialic acid precursors.
09/18/14
20140275485
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
The invention provides isolated anti-lp-pla2 antibodies that bind to lp-pla2. The invention also encompasses compositions comprising an anti-lp-pla2 antibody.
09/18/14
20140274909
Anti-cd22 chimeric antigen receptors
The disclosure provides a chimeric antigen receptor (car) comprising a) an antigen binding domain of ha22, a transmembrane domain, and an intracellular t cell signaling domain; or b) an antigen binding domain of bl22, a transmembrane domain, and an intracellular t cell signaling domain comprising cd28 and/or cd137. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
09/18/14
20140274885
Phi-4 polypeptides and methods for their use
Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
09/18/14
20140273208
Recombinant protein expression using a hybrid chef1 promoter
The invention provides expression vectors and host cells for high-level expression of recombinant proteins. The expression vectors comprise chinese hamster ovary elongation factor 1-α (chef1) transcriptional regulatory dna elements and a cytomegalovirus (cmv) promoter and/or a human adenovirus tripartite leader (adtpl) sequence.
09/18/14
20140273204
Method of producing a paralytic peptide
The invention relates to recombinant expression vectors encoding a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide..
09/18/14
20140273152
Recombinant manganese oxidase
Disclosed herein is a recombinant bacillus manganese oxidase complex, including a bacterial expression vector for the expression of the complex and a method of synthesizing the complex.. .
09/18/14
20140273096
Modified coagulation factors with prolonged in vivo half-life
The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor viii, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability.
09/18/14
20140273001
Feline bitter taste receptors and methods
A family of novel feline bitter taste receptors, referred to as feline tas2r (ftas2r), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors.
09/18/14
20140272988
Trans-splicing transcriptome profiling
The present invention provides a method of identifying mrna transcripts in the transcriptome of a cell comprising i) delivering into the cell a donor expression vector comprising nucleotides in a sequence encoding a trans-splicing barcode cassette, wherein the trans-splicing barcode cassette comprises a) a first portion, the nucleotide sequence of which encodes an intron comprising as part of its 3′ end, or followed at its 3′ end by a splice-site nucleotide sequence; followed at its 3′ end by, b) a second portion, the nucleotide sequence of which encodes a barcode polynucleotide; followed at its 3′ end by c) a third portion, which encodes a nucleotide identification element sequence, ii) exposing the cell to conditions such that the cell produces multiple copies of the trans-splicing barcode cassette encoded by the donor expression vector, which multiple copies of the trans-splicing barcode cassette each splice the barcode polynucleotide onto a mrna transcript of the cell, thereby forming multiple mrna transcripts of the cell, each spliced to the barcode polynucleotide; and iii) identifying the multiple mrna transcripts that are spliced to the barcode polynucleotides, thereby identifying mrna transcripts in the transcriptome of the cell.. .
09/18/14
20140271714
Induction of an immune response against dengue virus using the prime-boost approach
The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine.
09/18/14
20140271681
High affinity human antibodies to human il-4 receptor
The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (il-4r). Also provided are expression vectors comprising nucleic acid molecule that encode anti-il-4r antibodies, host cells comprising the expression vectors, and methods of producing anti-il-4r antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.
09/18/14
20140271676
Fc containing polypeptides with altered glycosylation and reduced effector function
Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the fc domain comprises: an asparagine residue at amino acid position 298, according to eu numbering; and a serine threonine residue at amino acid position 300, according to eu numbering.
09/18/14
20140271656
Optimized antigens of pneumocystis and use thereof
Immunologically active agents are described, including isolated pneumocystis a 12 protein or polypeptides; immunogenic conjugates containing pneumocystis a 12 protein or polypeptide of the present invention; antibodies recognizing the pneumocystis a 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the pneumocystis a 12 protein or polypeptide of the present invention, as well as dna constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and dna constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a pneumocystis organism, in a subject..
09/18/14
20140271607
Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
A blood coagulation factor vii derivative, a blood coagulation factor viia derivative, facvii and facviia conjugates are prepared by linking a polymer capable of extending the blood half-life to the derivative. Facvii and viia complexes each prepared by linking a carrier to the conjugate, genes encoding the facvii and facviia derivatives, expression vectors comprising the genes, transformants introduced with the expression vectors, a method for preparing the facvii and facviia derivatives using the transformants, a method for preparing the facviia conjugate and complex, a facviia complex prepared by the method, a pharmaceutical composition for the prevention or treatment of hemophilia comprising the derivative, conjugate, or complex as an active ingredient, and a pharmaceutical composition for blood coagulation comprising the derivative, conjugate, or complex as an active ingredient are described..
09/11/14
20140259223
Methods for producing cinnamolide and/or drimendiol
Described is a nucleic acid sequence isolated from persicaria hydropiper and encoding a drimenol oxidase protein, expression vectors comprising such nucleic acid sequence, chimeric genes comprising such nucleic acid sequence, host cells or host organisms altered to harbour the drimenol oxidase nucleic acid sequence, and the drimenol oxidase protein itself. Methods for producing cinnamolide and/or drimendiol and/or enhanced levels of cinnamolide and/or drimendiol, in a cell or organism harbouring such nucleic acid sequence are provided.
09/11/14
20140256800
Fev mini-promoters
Isolated polynucleotides comprising a fev mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
09/11/14
20140255415
Lingo binding molecules and pharmaceutical use thereof
The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human lingo polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with axonal degeneration and demyelination.. .
09/04/14
20140249302
Methods for making and using molecular switches involving circular permutation
The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways.
09/04/14
20140248701
Dcx mini-promoters
Isolated polynucleotides comprising a dcx mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
09/04/14
20140248295
Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
Disclosed herein are glycan-modified anti-cd4 monoclonal antibodies with n-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for hiv prevention and therapy are also disclosed..
09/04/14
20140248271
Novel human genes relating to respiratory diseases and obesity
This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein..
08/28/14
20140242648
Protein having activity to promote fatty acid chain elongation, gene encoding same and use thereof
The present invention relates to a protein having an activity to promote fatty acid chain elongation, a polynucleotide encoding the same, etc. The present invention provides, for example, a polynucleotide containing the nucleotide sequence shown in seq id no: 1 or 4, a polynucleotide encoding a protein which consists of the amino acid sequence shown in seq id no: 2, an expression vector and a transformant, each containing such a polynucleotide, a method for preparing lipids or fatty acids by using such a transformant, or a food or the like containing lipids or fatty acids prepared by such a method..
08/28/14
20140242647
In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes
The present invention provides methods for catalyzing the conversion of an olefin to any compound containing one or more cyclopropane functional groups using heme enzymes. In certain aspects, the present invention provides a method for producing a cyclopropanation product comprising providing an olefinic substrate, a diazo reagent, and a heme enzyme; and admixing the components in a reaction for a time sufficient to produce a cyclopropanation product.
08/28/14
20140242638
Transcription unit and use thereof in (yb2/0) expression vectors
A transcription unit constituted by a polynucleotide including the hcmvie virus enhancer, the enhancer having the nucleotide sequence seq id no: 1, or a nucleotide acid having at least 70% sequence identity with the sequence seq id no: 1 and essentially having transcription activation properties, and the promoter region of cyclin-dependent kinase 9 (cdk9), the promoter region having the nucleotide sequence seq id no: 2, or a nucleotide acid having at least 70% sequence identity with the sequence seq id no: 2 and essentially having a promoter activity.. .
08/28/14
20140242114
Cdna construct of salmonidae alphavirus
The invention concerns recombinant dna's comprising cdna of genomic rna of a salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant dnas are useful for obtaining expression vectors, producing recombinant salmonidae alphavirus, and for obtaining vaccines..
08/28/14
20140242086
Polynucleotides encoding signal peptide-containing molecules
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
08/28/14
20140242077
Methods and compositions for modulating an immune response
Provided are multispecific binding proteins and methods for using these multispecific binding proteins to modulate the activation state of immune cells, such as t-cells (e.g., cytotoxic t-cells). Also provided are methods of modulating an immune response (e.g., cell killing by cytotoxic t-cells) in a subject (e.g., a human subject).
08/21/14
20140235823
Fusion protein containing a single-stranded dna binding protein and methods for expression and purification of the same
The present invention provides an expression vector comprising a promoter and a polynucleotide sequence encoding a fusion protein. The present invention further provides a method for purification of an interest protein.
08/21/14
20140234933
Egvii endoglucanase and nucleic acids encoding the same
The present invention provides a novel endoglucanase nucleic acid sequence, designated egl7, and the corresponding egvii amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding egvii, recombinant egvii proteins and methods for producing the same..
08/21/14
20140234932
Bgl7 beta-glucosidase and nucleic acids encoding the same
The present invention provides a novel β-glucosidase nucleic acid sequence, designated bgl7, and the corresponding bgl7 amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding bgl7, recombinant bgl7 proteins and methods for producing the same..
08/21/14
20140234931
Bgl6 beta-glucosidase and nucleic acids encoding the same
The present invention provides a novel β-glucosidase nucleic acid sequence, designated bgl6, and the corresponding bgl6 amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding bgl6, recombinant bgl6 proteins and methods for producing the same..
08/21/14
20140234361
Novel expression vectors and uses thereof
A method for treating an hiv disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a dna vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a dna sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a dna binding domain which binds to a specific dna binding sequence, and (ii) a functional domain of the bovine papilloma virus type 1 e2 protein, where the functional domain binds to a nuclear component; (b) a multimerized dna sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a dna sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.. .


Popular terms: [SEARCH]

Expression Vector topics: Expression Vector, Recombinant, Nucleic Acid, Antibodies, Polypeptide, Amino Acid, Amino Acid Sequence, Nucleic Acids, Polynucleotide, Nucleotide, Cytomegalovirus, Endothelial, Extracellular, Endothelial Cell, Epithelial

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Expression Vector for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Vector with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.4863

3876

0 - 1 - 73